nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyl aminolevulinate—Aminolevulinic acid—ALAD—epilepsy syndrome	0.0376	1	CrCbGaD
Methyl aminolevulinate—FCGR1A—FCGR activation—FYN—epilepsy syndrome	0.012	0.111	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Regulation of actin dynamics for phagocytic cup formation—ACTB—epilepsy syndrome	0.00597	0.0553	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—FCGR activation—SRC—epilepsy syndrome	0.00559	0.0518	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—ACTB—epilepsy syndrome	0.00451	0.0418	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Regulation of actin dynamics for phagocytic cup formation—CDC42—epilepsy syndrome	0.00413	0.0382	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—SOCS3—epilepsy syndrome	0.00355	0.0329	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—CDC42—epilepsy syndrome	0.00312	0.0289	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—EIF2AK2—epilepsy syndrome	0.003	0.0278	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—FYN—epilepsy syndrome	0.00277	0.0257	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—UBE3A—epilepsy syndrome	0.0026	0.0241	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—PARK2—epilepsy syndrome	0.00205	0.019	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—EIF2AK2—epilepsy syndrome	0.002	0.0186	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—P2RX7—epilepsy syndrome	0.00199	0.0185	CbGpPWpGaD
Methyl aminolevulinate—Infection—Felbamate—epilepsy syndrome	0.00177	0.00207	CcSEcCtD
Methyl aminolevulinate—Urticaria—Acetazolamide—epilepsy syndrome	0.00176	0.00206	CcSEcCtD
Methyl aminolevulinate—Pain—Propofol—epilepsy syndrome	0.00176	0.00206	CcSEcCtD
Methyl aminolevulinate—Pruritus—Clobazam—epilepsy syndrome	0.00176	0.00206	CcSEcCtD
Methyl aminolevulinate—Rash—Phenobarbital—epilepsy syndrome	0.00175	0.00205	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Phenobarbital—epilepsy syndrome	0.00175	0.00205	CcSEcCtD
Methyl aminolevulinate—Oedema—Zonisamide—epilepsy syndrome	0.00174	0.00204	CcSEcCtD
Methyl aminolevulinate—Headache—Phenobarbital—epilepsy syndrome	0.00174	0.00204	CcSEcCtD
Methyl aminolevulinate—Fatigue—Midazolam—epilepsy syndrome	0.00174	0.00203	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—SOCS3—epilepsy syndrome	0.00173	0.0161	CbGpPWpGaD
Methyl aminolevulinate—Infection—Zonisamide—epilepsy syndrome	0.00173	0.00203	CcSEcCtD
Methyl aminolevulinate—Discomfort—Clonazepam—epilepsy syndrome	0.00173	0.00203	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Fosphenytoin—epilepsy syndrome	0.00172	0.00202	CcSEcCtD
Methyl aminolevulinate—Pain—Midazolam—epilepsy syndrome	0.00172	0.00201	CcSEcCtD
Methyl aminolevulinate—Discomfort—Phenytoin—epilepsy syndrome	0.00172	0.00201	CcSEcCtD
Methyl aminolevulinate—Rash—Rufinamide—epilepsy syndrome	0.00172	0.00201	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Rufinamide—epilepsy syndrome	0.00172	0.00201	CcSEcCtD
Methyl aminolevulinate—Fatigue—Levetiracetam—epilepsy syndrome	0.00171	0.00201	CcSEcCtD
Methyl aminolevulinate—Discomfort—Oxcarbazepine—epilepsy syndrome	0.00171	0.002	CcSEcCtD
Methyl aminolevulinate—Headache—Rufinamide—epilepsy syndrome	0.00171	0.002	CcSEcCtD
Methyl aminolevulinate—Pain—Levetiracetam—epilepsy syndrome	0.0017	0.00199	CcSEcCtD
Methyl aminolevulinate—Dizziness—Lacosamide—epilepsy syndrome	0.00169	0.00198	CcSEcCtD
Methyl aminolevulinate—Oedema—Clonazepam—epilepsy syndrome	0.00168	0.00197	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Vigabatrin—epilepsy syndrome	0.00168	0.00197	CcSEcCtD
Methyl aminolevulinate—Face oedema—Topiramate—epilepsy syndrome	0.00168	0.00196	CcSEcCtD
Methyl aminolevulinate—Infection—Clonazepam—epilepsy syndrome	0.00167	0.00195	CcSEcCtD
Methyl aminolevulinate—Infection—Phenytoin—epilepsy syndrome	0.00166	0.00194	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Diazepam—epilepsy syndrome	0.00165	0.00194	CcSEcCtD
Methyl aminolevulinate—Nausea—Phenobarbital—epilepsy syndrome	0.00165	0.00193	CcSEcCtD
Methyl aminolevulinate—Infection—Oxcarbazepine—epilepsy syndrome	0.00165	0.00193	CcSEcCtD
Methyl aminolevulinate—Dizziness—Clobazam—epilepsy syndrome	0.00164	0.00192	CcSEcCtD
Methyl aminolevulinate—Urticaria—Propofol—epilepsy syndrome	0.00163	0.00191	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Gabapentin—epilepsy syndrome	0.00163	0.00191	CcSEcCtD
Methyl aminolevulinate—Nausea—Rufinamide—epilepsy syndrome	0.00162	0.0019	CcSEcCtD
Methyl aminolevulinate—Rash—Lacosamide—epilepsy syndrome	0.00161	0.00189	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Lacosamide—epilepsy syndrome	0.00161	0.00189	CcSEcCtD
Methyl aminolevulinate—Fatigue—Vigabatrin—epilepsy syndrome	0.00161	0.00189	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Valproic Acid—epilepsy syndrome	0.00161	0.00188	CcSEcCtD
Methyl aminolevulinate—Headache—Lacosamide—epilepsy syndrome	0.0016	0.00188	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Felbamate—epilepsy syndrome	0.0016	0.00187	CcSEcCtD
Methyl aminolevulinate—Pain—Vigabatrin—epilepsy syndrome	0.0016	0.00187	CcSEcCtD
Methyl aminolevulinate—Urticaria—Midazolam—epilepsy syndrome	0.0016	0.00187	CcSEcCtD
Methyl aminolevulinate—Oedema—Carbamazepine—epilepsy syndrome	0.00159	0.00187	CcSEcCtD
Methyl aminolevulinate—Asthenia—Acetazolamide—epilepsy syndrome	0.00159	0.00186	CcSEcCtD
Methyl aminolevulinate—Discomfort—Lamotrigine—epilepsy syndrome	0.00159	0.00186	CcSEcCtD
Methyl aminolevulinate—Fatigue—Diazepam—epilepsy syndrome	0.00159	0.00186	CcSEcCtD
Methyl aminolevulinate—Infection—Carbamazepine—epilepsy syndrome	0.00158	0.00185	CcSEcCtD
Methyl aminolevulinate—Pain—Diazepam—epilepsy syndrome	0.00157	0.00184	CcSEcCtD
Methyl aminolevulinate—Rash—Clobazam—epilepsy syndrome	0.00157	0.00183	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Zonisamide—epilepsy syndrome	0.00157	0.00183	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Clobazam—epilepsy syndrome	0.00157	0.00183	CcSEcCtD
Methyl aminolevulinate—Headache—Clobazam—epilepsy syndrome	0.00156	0.00182	CcSEcCtD
Methyl aminolevulinate—Oedema—Lamotrigine—epilepsy syndrome	0.00154	0.0018	CcSEcCtD
Methyl aminolevulinate—Fatigue—Felbamate—epilepsy syndrome	0.00154	0.0018	CcSEcCtD
Methyl aminolevulinate—Infection—Lamotrigine—epilepsy syndrome	0.00153	0.00179	CcSEcCtD
Methyl aminolevulinate—Urticaria—Fosphenytoin—epilepsy syndrome	0.00152	0.00178	CcSEcCtD
Methyl aminolevulinate—Pain—Felbamate—epilepsy syndrome	0.00152	0.00178	CcSEcCtD
Methyl aminolevulinate—Nausea—Lacosamide—epilepsy syndrome	0.00152	0.00178	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—CASP1—epilepsy syndrome	0.00152	0.0141	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—PTK2B—epilepsy syndrome	0.00152	0.0141	CbGpPWpGaD
Methyl aminolevulinate—Fatigue—Zonisamide—epilepsy syndrome	0.0015	0.00176	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Phenytoin—epilepsy syndrome	0.0015	0.00175	CcSEcCtD
Methyl aminolevulinate—Urticaria—Vigabatrin—epilepsy syndrome	0.00149	0.00174	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Midazolam—epilepsy syndrome	0.00148	0.00174	CcSEcCtD
Methyl aminolevulinate—Nausea—Clobazam—epilepsy syndrome	0.00148	0.00173	CcSEcCtD
Methyl aminolevulinate—Asthenia—Propofol—epilepsy syndrome	0.00148	0.00173	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL1RN—epilepsy syndrome	0.00147	0.0136	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Acetazolamide—epilepsy syndrome	0.00147	0.00171	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Levetiracetam—epilepsy syndrome	0.00146	0.00171	CcSEcCtD
Methyl aminolevulinate—Urticaria—Diazepam—epilepsy syndrome	0.00146	0.00171	CcSEcCtD
Methyl aminolevulinate—Pruritus—Propofol—epilepsy syndrome	0.00146	0.0017	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Pregabalin—epilepsy syndrome	0.00146	0.0017	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—DUSP4—epilepsy syndrome	0.00145	0.0135	CbGpPWpGaD
Methyl aminolevulinate—Fatigue—Clonazepam—epilepsy syndrome	0.00145	0.0017	CcSEcCtD
Methyl aminolevulinate—Asthenia—Midazolam—epilepsy syndrome	0.00144	0.00169	CcSEcCtD
Methyl aminolevulinate—Fatigue—Phenytoin—epilepsy syndrome	0.00144	0.00169	CcSEcCtD
Methyl aminolevulinate—Pain—Clonazepam—epilepsy syndrome	0.00144	0.00168	CcSEcCtD
Methyl aminolevulinate—Fatigue—Oxcarbazepine—epilepsy syndrome	0.00143	0.00168	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Carbamazepine—epilepsy syndrome	0.00143	0.00168	CcSEcCtD
Methyl aminolevulinate—Asthenia—Levetiracetam—epilepsy syndrome	0.00143	0.00167	CcSEcCtD
Methyl aminolevulinate—Pruritus—Midazolam—epilepsy syndrome	0.00142	0.00167	CcSEcCtD
Methyl aminolevulinate—Pain—Oxcarbazepine—epilepsy syndrome	0.00142	0.00166	CcSEcCtD
Methyl aminolevulinate—Urticaria—Felbamate—epilepsy syndrome	0.00142	0.00166	CcSEcCtD
Methyl aminolevulinate—Pruritus—Levetiracetam—epilepsy syndrome	0.00141	0.00165	CcSEcCtD
Methyl aminolevulinate—Headache—Acetazolamide—epilepsy syndrome	0.00139	0.00162	CcSEcCtD
Methyl aminolevulinate—Urticaria—Zonisamide—epilepsy syndrome	0.00139	0.00162	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Lamotrigine—epilepsy syndrome	0.00138	0.00162	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Vigabatrin—epilepsy syndrome	0.00138	0.00161	CcSEcCtD
Methyl aminolevulinate—Asthenia—Fosphenytoin—epilepsy syndrome	0.00138	0.00161	CcSEcCtD
Methyl aminolevulinate—Fatigue—Carbamazepine—epilepsy syndrome	0.00137	0.00161	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Topiramate—epilepsy syndrome	0.00137	0.0016	CcSEcCtD
Methyl aminolevulinate—Pain—Carbamazepine—epilepsy syndrome	0.00136	0.0016	CcSEcCtD
Methyl aminolevulinate—Dizziness—Propofol—epilepsy syndrome	0.00136	0.00159	CcSEcCtD
Methyl aminolevulinate—Pruritus—Fosphenytoin—epilepsy syndrome	0.00136	0.00159	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Diazepam—epilepsy syndrome	0.00136	0.00159	CcSEcCtD
Methyl aminolevulinate—Asthenia—Vigabatrin—epilepsy syndrome	0.00134	0.00157	CcSEcCtD
Methyl aminolevulinate—Urticaria—Clonazepam—epilepsy syndrome	0.00134	0.00156	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Gabapentin—epilepsy syndrome	0.00134	0.00156	CcSEcCtD
Methyl aminolevulinate—Dizziness—Midazolam—epilepsy syndrome	0.00133	0.00156	CcSEcCtD
Methyl aminolevulinate—Fatigue—Lamotrigine—epilepsy syndrome	0.00133	0.00155	CcSEcCtD
Methyl aminolevulinate—Urticaria—Phenytoin—epilepsy syndrome	0.00133	0.00155	CcSEcCtD
Methyl aminolevulinate—Pruritus—Vigabatrin—epilepsy syndrome	0.00132	0.00155	CcSEcCtD
Methyl aminolevulinate—Asthenia—Diazepam—epilepsy syndrome	0.00132	0.00155	CcSEcCtD
Methyl aminolevulinate—Urticaria—Oxcarbazepine—epilepsy syndrome	0.00132	0.00154	CcSEcCtD
Methyl aminolevulinate—Pain—Lamotrigine—epilepsy syndrome	0.00132	0.00154	CcSEcCtD
Methyl aminolevulinate—Nausea—Acetazolamide—epilepsy syndrome	0.00132	0.00154	CcSEcCtD
Methyl aminolevulinate—Dizziness—Levetiracetam—epilepsy syndrome	0.00131	0.00154	CcSEcCtD
Methyl aminolevulinate—Pruritus—Diazepam—epilepsy syndrome	0.0013	0.00152	CcSEcCtD
Methyl aminolevulinate—Rash—Propofol—epilepsy syndrome	0.0013	0.00152	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Propofol—epilepsy syndrome	0.0013	0.00152	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—SRC—epilepsy syndrome	0.00129	0.012	CbGpPWpGaD
Methyl aminolevulinate—Headache—Propofol—epilepsy syndrome	0.00129	0.00151	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—UBE3A—epilepsy syndrome	0.00129	0.0119	CbGpPWpGaD
Methyl aminolevulinate—Hypersensitivity—Zonisamide—epilepsy syndrome	0.00129	0.0015	CcSEcCtD
Methyl aminolevulinate—Asthenia—Felbamate—epilepsy syndrome	0.00128	0.0015	CcSEcCtD
Methyl aminolevulinate—Rash—Midazolam—epilepsy syndrome	0.00127	0.00149	CcSEcCtD
Methyl aminolevulinate—Dizziness—Fosphenytoin—epilepsy syndrome	0.00127	0.00148	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Midazolam—epilepsy syndrome	0.00127	0.00148	CcSEcCtD
Methyl aminolevulinate—Urticaria—Carbamazepine—epilepsy syndrome	0.00127	0.00148	CcSEcCtD
Methyl aminolevulinate—Discomfort—Valproic Acid—epilepsy syndrome	0.00126	0.00148	CcSEcCtD
Methyl aminolevulinate—Headache—Midazolam—epilepsy syndrome	0.00126	0.00148	CcSEcCtD
Methyl aminolevulinate—Pruritus—Felbamate—epilepsy syndrome	0.00126	0.00148	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—SOCS3—epilepsy syndrome	0.00126	0.0117	CbGpPWpGaD
Methyl aminolevulinate—Rash—Levetiracetam—epilepsy syndrome	0.00125	0.00147	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Levetiracetam—epilepsy syndrome	0.00125	0.00147	CcSEcCtD
Methyl aminolevulinate—Asthenia—Zonisamide—epilepsy syndrome	0.00125	0.00146	CcSEcCtD
Methyl aminolevulinate—Headache—Levetiracetam—epilepsy syndrome	0.00125	0.00146	CcSEcCtD
Methyl aminolevulinate—Erythema—Gabapentin—epilepsy syndrome	0.00124	0.00146	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Clonazepam—epilepsy syndrome	0.00124	0.00145	CcSEcCtD
Methyl aminolevulinate—Dizziness—Vigabatrin—epilepsy syndrome	0.00124	0.00145	CcSEcCtD
Methyl aminolevulinate—Pruritus—Zonisamide—epilepsy syndrome	0.00123	0.00144	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Phenytoin—epilepsy syndrome	0.00123	0.00144	CcSEcCtD
Methyl aminolevulinate—Oedema—Valproic Acid—epilepsy syndrome	0.00122	0.00143	CcSEcCtD
Methyl aminolevulinate—Urticaria—Lamotrigine—epilepsy syndrome	0.00122	0.00143	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Oxcarbazepine—epilepsy syndrome	0.00122	0.00143	CcSEcCtD
Methyl aminolevulinate—Nausea—Propofol—epilepsy syndrome	0.00122	0.00143	CcSEcCtD
Methyl aminolevulinate—Dizziness—Diazepam—epilepsy syndrome	0.00122	0.00143	CcSEcCtD
Methyl aminolevulinate—Infection—Valproic Acid—epilepsy syndrome	0.00122	0.00142	CcSEcCtD
Methyl aminolevulinate—Rash—Fosphenytoin—epilepsy syndrome	0.00121	0.00142	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Fosphenytoin—epilepsy syndrome	0.00121	0.00141	CcSEcCtD
Methyl aminolevulinate—Asthenia—Clonazepam—epilepsy syndrome	0.00121	0.00141	CcSEcCtD
Methyl aminolevulinate—Headache—Fosphenytoin—epilepsy syndrome	0.0012	0.00141	CcSEcCtD
Methyl aminolevulinate—Asthenia—Phenytoin—epilepsy syndrome	0.0012	0.0014	CcSEcCtD
Methyl aminolevulinate—Nausea—Midazolam—epilepsy syndrome	0.0012	0.0014	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CASP2—epilepsy syndrome	0.00119	0.0111	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Oxcarbazepine—epilepsy syndrome	0.00119	0.00139	CcSEcCtD
Methyl aminolevulinate—Pruritus—Clonazepam—epilepsy syndrome	0.00119	0.00139	CcSEcCtD
Methyl aminolevulinate—Pruritus—Phenytoin—epilepsy syndrome	0.00118	0.00138	CcSEcCtD
Methyl aminolevulinate—Nausea—Levetiracetam—epilepsy syndrome	0.00118	0.00138	CcSEcCtD
Methyl aminolevulinate—Rash—Vigabatrin—epilepsy syndrome	0.00118	0.00138	CcSEcCtD
Methyl aminolevulinate—Dizziness—Felbamate—epilepsy syndrome	0.00118	0.00138	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Vigabatrin—epilepsy syndrome	0.00118	0.00138	CcSEcCtD
Methyl aminolevulinate—Pruritus—Oxcarbazepine—epilepsy syndrome	0.00118	0.00138	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Carbamazepine—epilepsy syndrome	0.00117	0.00137	CcSEcCtD
Methyl aminolevulinate—Headache—Vigabatrin—epilepsy syndrome	0.00117	0.00137	CcSEcCtD
Methyl aminolevulinate—Rash—Diazepam—epilepsy syndrome	0.00116	0.00136	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—P2RX7—epilepsy syndrome	0.00116	0.0108	CbGpPWpGaD
Methyl aminolevulinate—Dermatitis—Diazepam—epilepsy syndrome	0.00116	0.00136	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—SOCS3—epilepsy syndrome	0.00116	0.0107	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Zonisamide—epilepsy syndrome	0.00115	0.00135	CcSEcCtD
Methyl aminolevulinate—Headache—Diazepam—epilepsy syndrome	0.00115	0.00135	CcSEcCtD
Methyl aminolevulinate—Asthenia—Carbamazepine—epilepsy syndrome	0.00114	0.00134	CcSEcCtD
Methyl aminolevulinate—Discomfort—Pregabalin—epilepsy syndrome	0.00114	0.00133	CcSEcCtD
Methyl aminolevulinate—Nausea—Fosphenytoin—epilepsy syndrome	0.00114	0.00133	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Lamotrigine—epilepsy syndrome	0.00114	0.00133	CcSEcCtD
Methyl aminolevulinate—Pruritus—Carbamazepine—epilepsy syndrome	0.00113	0.00132	CcSEcCtD
Methyl aminolevulinate—Rash—Felbamate—epilepsy syndrome	0.00112	0.00132	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Topiramate—epilepsy syndrome	0.00112	0.00131	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Felbamate—epilepsy syndrome	0.00112	0.00131	CcSEcCtD
Methyl aminolevulinate—Headache—Felbamate—epilepsy syndrome	0.00112	0.00131	CcSEcCtD
Methyl aminolevulinate—Dizziness—Clonazepam—epilepsy syndrome	0.00111	0.0013	CcSEcCtD
Methyl aminolevulinate—Nausea—Vigabatrin—epilepsy syndrome	0.00111	0.0013	CcSEcCtD
Methyl aminolevulinate—Oedema—Pregabalin—epilepsy syndrome	0.00111	0.0013	CcSEcCtD
Methyl aminolevulinate—Asthenia—Lamotrigine—epilepsy syndrome	0.00111	0.00129	CcSEcCtD
Methyl aminolevulinate—Dizziness—Phenytoin—epilepsy syndrome	0.0011	0.00129	CcSEcCtD
Methyl aminolevulinate—Rash—Zonisamide—epilepsy syndrome	0.0011	0.00129	CcSEcCtD
Methyl aminolevulinate—Infection—Pregabalin—epilepsy syndrome	0.0011	0.00129	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Valproic Acid—epilepsy syndrome	0.0011	0.00129	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Zonisamide—epilepsy syndrome	0.0011	0.00129	CcSEcCtD
Methyl aminolevulinate—Dizziness—Oxcarbazepine—epilepsy syndrome	0.0011	0.00129	CcSEcCtD
Methyl aminolevulinate—Nausea—Diazepam—epilepsy syndrome	0.00109	0.00128	CcSEcCtD
Methyl aminolevulinate—Headache—Zonisamide—epilepsy syndrome	0.00109	0.00128	CcSEcCtD
Methyl aminolevulinate—Pruritus—Lamotrigine—epilepsy syndrome	0.00109	0.00128	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—MAPK10—epilepsy syndrome	0.00107	0.00994	CbGpPWpGaD
Methyl aminolevulinate—Rash—Clonazepam—epilepsy syndrome	0.00106	0.00124	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Clonazepam—epilepsy syndrome	0.00106	0.00124	CcSEcCtD
Methyl aminolevulinate—Nausea—Felbamate—epilepsy syndrome	0.00106	0.00124	CcSEcCtD
Methyl aminolevulinate—Fatigue—Valproic Acid—epilepsy syndrome	0.00106	0.00124	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL18—epilepsy syndrome	0.00106	0.00978	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Carbamazepine—epilepsy syndrome	0.00105	0.00123	CcSEcCtD
Methyl aminolevulinate—Headache—Clonazepam—epilepsy syndrome	0.00105	0.00123	CcSEcCtD
Methyl aminolevulinate—Rash—Phenytoin—epilepsy syndrome	0.00105	0.00123	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Phenytoin—epilepsy syndrome	0.00105	0.00123	CcSEcCtD
Methyl aminolevulinate—Rash—Oxcarbazepine—epilepsy syndrome	0.00105	0.00123	CcSEcCtD
Methyl aminolevulinate—Pain—Valproic Acid—epilepsy syndrome	0.00105	0.00123	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Oxcarbazepine—epilepsy syndrome	0.00105	0.00122	CcSEcCtD
Methyl aminolevulinate—Headache—Phenytoin—epilepsy syndrome	0.00105	0.00122	CcSEcCtD
Methyl aminolevulinate—Erythema—Topiramate—epilepsy syndrome	0.00105	0.00122	CcSEcCtD
Methyl aminolevulinate—Discomfort—Gabapentin—epilepsy syndrome	0.00105	0.00122	CcSEcCtD
Methyl aminolevulinate—Headache—Oxcarbazepine—epilepsy syndrome	0.00104	0.00122	CcSEcCtD
Methyl aminolevulinate—Nausea—Zonisamide—epilepsy syndrome	0.00104	0.00121	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—FYN—epilepsy syndrome	0.00103	0.00953	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Lamotrigine—epilepsy syndrome	0.00102	0.00119	CcSEcCtD
Methyl aminolevulinate—Oedema—Gabapentin—epilepsy syndrome	0.00101	0.00119	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PARK2—epilepsy syndrome	0.00101	0.00939	CbGpPWpGaD
Methyl aminolevulinate—Infection—Gabapentin—epilepsy syndrome	0.00101	0.00118	CcSEcCtD
Methyl aminolevulinate—Rash—Carbamazepine—epilepsy syndrome	0.00101	0.00118	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Carbamazepine—epilepsy syndrome	0.001	0.00118	CcSEcCtD
Methyl aminolevulinate—Nausea—Clonazepam—epilepsy syndrome	0.000999	0.00117	CcSEcCtD
Methyl aminolevulinate—Headache—Carbamazepine—epilepsy syndrome	0.000999	0.00117	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Pregabalin—epilepsy syndrome	0.000994	0.00116	CcSEcCtD
Methyl aminolevulinate—Nausea—Phenytoin—epilepsy syndrome	0.000992	0.00116	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—YWHAZ—epilepsy syndrome	0.000988	0.00916	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Oxcarbazepine—epilepsy syndrome	0.000987	0.00115	CcSEcCtD
Methyl aminolevulinate—Urticaria—Valproic Acid—epilepsy syndrome	0.000973	0.00114	CcSEcCtD
Methyl aminolevulinate—Rash—Lamotrigine—epilepsy syndrome	0.000971	0.00114	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Lamotrigine—epilepsy syndrome	0.000971	0.00114	CcSEcCtD
Methyl aminolevulinate—Headache—Lamotrigine—epilepsy syndrome	0.000965	0.00113	CcSEcCtD
Methyl aminolevulinate—Fatigue—Pregabalin—epilepsy syndrome	0.000954	0.00112	CcSEcCtD
Methyl aminolevulinate—Nausea—Carbamazepine—epilepsy syndrome	0.000947	0.00111	CcSEcCtD
Methyl aminolevulinate—Pain—Pregabalin—epilepsy syndrome	0.000947	0.00111	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—ACTB—epilepsy syndrome	0.000937	0.00868	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Lamotrigine—epilepsy syndrome	0.000915	0.00107	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Gabapentin—epilepsy syndrome	0.000911	0.00107	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Valproic Acid—epilepsy syndrome	0.000902	0.00106	CcSEcCtD
Methyl aminolevulinate—Discomfort—Topiramate—epilepsy syndrome	0.00088	0.00103	CcSEcCtD
Methyl aminolevulinate—Urticaria—Pregabalin—epilepsy syndrome	0.000879	0.00103	CcSEcCtD
Methyl aminolevulinate—Asthenia—Valproic Acid—epilepsy syndrome	0.000878	0.00103	CcSEcCtD
Methyl aminolevulinate—Fatigue—Gabapentin—epilepsy syndrome	0.000875	0.00102	CcSEcCtD
Methyl aminolevulinate—Pain—Gabapentin—epilepsy syndrome	0.000868	0.00102	CcSEcCtD
Methyl aminolevulinate—Pruritus—Valproic Acid—epilepsy syndrome	0.000866	0.00101	CcSEcCtD
Methyl aminolevulinate—Oedema—Topiramate—epilepsy syndrome	0.000854	0.000999	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CASP1—epilepsy syndrome	0.000851	0.00788	CbGpPWpGaD
Methyl aminolevulinate—Infection—Topiramate—epilepsy syndrome	0.000848	0.000993	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—DUSP4—epilepsy syndrome	0.000847	0.00785	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CCR2—epilepsy syndrome	0.000827	0.00767	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—DUSP6—epilepsy syndrome	0.00082	0.0076	CbGpPWpGaD
Methyl aminolevulinate—Hypersensitivity—Pregabalin—epilepsy syndrome	0.000815	0.000954	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL6ST—epilepsy syndrome	0.000812	0.00753	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Valproic Acid—epilepsy syndrome	0.00081	0.000947	CcSEcCtD
Methyl aminolevulinate—Urticaria—Gabapentin—epilepsy syndrome	0.000806	0.000944	CcSEcCtD
Methyl aminolevulinate—Asthenia—Pregabalin—epilepsy syndrome	0.000794	0.000929	CcSEcCtD
Methyl aminolevulinate—Pruritus—Pregabalin—epilepsy syndrome	0.000783	0.000916	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—UBE3A—epilepsy syndrome	0.00078	0.00723	CbGpPWpGaD
Methyl aminolevulinate—Rash—Valproic Acid—epilepsy syndrome	0.000772	0.000903	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Valproic Acid—epilepsy syndrome	0.000771	0.000903	CcSEcCtD
Methyl aminolevulinate—Headache—Valproic Acid—epilepsy syndrome	0.000767	0.000898	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Topiramate—epilepsy syndrome	0.000767	0.000897	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Gabapentin—epilepsy syndrome	0.000748	0.000875	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CD40—epilepsy syndrome	0.000739	0.00685	CbGpPWpGaD
Methyl aminolevulinate—Fatigue—Topiramate—epilepsy syndrome	0.000736	0.000862	CcSEcCtD
Methyl aminolevulinate—Dizziness—Pregabalin—epilepsy syndrome	0.000732	0.000857	CcSEcCtD
Methyl aminolevulinate—Pain—Topiramate—epilepsy syndrome	0.00073	0.000855	CcSEcCtD
Methyl aminolevulinate—Asthenia—Gabapentin—epilepsy syndrome	0.000728	0.000852	CcSEcCtD
Methyl aminolevulinate—Nausea—Valproic Acid—epilepsy syndrome	0.000727	0.000851	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—HBEGF—epilepsy syndrome	0.000723	0.0067	CbGpPWpGaD
Methyl aminolevulinate—Pruritus—Gabapentin—epilepsy syndrome	0.000718	0.00084	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—AKT3—epilepsy syndrome	0.00071	0.00658	CbGpPWpGaD
Methyl aminolevulinate—Rash—Pregabalin—epilepsy syndrome	0.000698	0.000817	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Pregabalin—epilepsy syndrome	0.000697	0.000816	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—CASP2—epilepsy syndrome	0.000695	0.00644	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—HBEGF—epilepsy syndrome	0.000694	0.00644	CbGpPWpGaD
Methyl aminolevulinate—Headache—Pregabalin—epilepsy syndrome	0.000693	0.000811	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—AKT3—epilepsy syndrome	0.000682	0.00632	CbGpPWpGaD
Methyl aminolevulinate—Urticaria—Topiramate—epilepsy syndrome	0.000678	0.000794	CcSEcCtD
Methyl aminolevulinate—Dizziness—Gabapentin—epilepsy syndrome	0.000671	0.000785	CcSEcCtD
Methyl aminolevulinate—Nausea—Pregabalin—epilepsy syndrome	0.000657	0.000769	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—S100B—epilepsy syndrome	0.000656	0.00608	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—EIF2AK2—epilepsy syndrome	0.000654	0.00606	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CDC42—epilepsy syndrome	0.000648	0.006	CbGpPWpGaD
Methyl aminolevulinate—Rash—Gabapentin—epilepsy syndrome	0.00064	0.000749	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Gabapentin—epilepsy syndrome	0.000639	0.000748	CcSEcCtD
Methyl aminolevulinate—Headache—Gabapentin—epilepsy syndrome	0.000636	0.000744	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Topiramate—epilepsy syndrome	0.000629	0.000736	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—MAPK10—epilepsy syndrome	0.000625	0.00579	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—SOCS3—epilepsy syndrome	0.000623	0.00578	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CDC42—epilepsy syndrome	0.000622	0.00576	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PARK2—epilepsy syndrome	0.000615	0.0057	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Topiramate—epilepsy syndrome	0.000613	0.000717	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—RELA—epilepsy syndrome	0.00061	0.00565	CbGpPWpGaD
Methyl aminolevulinate—Pruritus—Topiramate—epilepsy syndrome	0.000604	0.000707	CcSEcCtD
Methyl aminolevulinate—Nausea—Gabapentin—epilepsy syndrome	0.000603	0.000706	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—FYN—epilepsy syndrome	0.000577	0.00534	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—MEF2C—epilepsy syndrome	0.000574	0.00532	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Topiramate—epilepsy syndrome	0.000565	0.000661	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—FYN—epilepsy syndrome	0.000554	0.00513	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL1B—epilepsy syndrome	0.000551	0.00511	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—ACTB—epilepsy syndrome	0.000546	0.00506	CbGpPWpGaD
Methyl aminolevulinate—Rash—Topiramate—epilepsy syndrome	0.000538	0.00063	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Topiramate—epilepsy syndrome	0.000538	0.000629	CcSEcCtD
Methyl aminolevulinate—Headache—Topiramate—epilepsy syndrome	0.000535	0.000626	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—YWHAZ—epilepsy syndrome	0.000532	0.00493	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Topiramate—epilepsy syndrome	0.000507	0.000594	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—TSC2—epilepsy syndrome	0.000496	0.00459	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CRP—epilepsy syndrome	0.000496	0.00459	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PTK2B—epilepsy syndrome	0.000495	0.00459	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CASP1—epilepsy syndrome	0.000495	0.00459	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CCR2—epilepsy syndrome	0.000482	0.00447	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IL1RN—epilepsy syndrome	0.00048	0.00445	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—DUSP6—epilepsy syndrome	0.000478	0.00443	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—TSC2—epilepsy syndrome	0.000476	0.00441	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—IL6ST—epilepsy syndrome	0.000456	0.00422	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CD40—epilepsy syndrome	0.000448	0.00415	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PRKCB—epilepsy syndrome	0.000439	0.00407	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—HBEGF—epilepsy syndrome	0.000421	0.0039	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—FOS—epilepsy syndrome	0.000417	0.00387	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—AKT3—epilepsy syndrome	0.000413	0.00383	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CASP8—epilepsy syndrome	0.000408	0.00378	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—S100B—epilepsy syndrome	0.000382	0.00354	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—SOCS3—epilepsy syndrome	0.000378	0.0035	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CDC42—epilepsy syndrome	0.000377	0.0035	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—FGF2—epilepsy syndrome	0.000368	0.00342	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—FGF2—epilepsy syndrome	0.000354	0.00328	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—BCL2—epilepsy syndrome	0.00035	0.00324	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IL18—epilepsy syndrome	0.000345	0.00319	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—RELA—epilepsy syndrome	0.000342	0.00317	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—FYN—epilepsy syndrome	0.000336	0.00311	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—MTOR—epilepsy syndrome	0.000335	0.00311	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—MEF2C—epilepsy syndrome	0.000334	0.0031	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—RELA—epilepsy syndrome	0.000328	0.00304	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—YWHAZ—epilepsy syndrome	0.000323	0.00299	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—MTOR—epilepsy syndrome	0.000322	0.00299	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—JUN—epilepsy syndrome	0.0003	0.00278	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CRP—epilepsy syndrome	0.000289	0.00268	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—TSC2—epilepsy syndrome	0.000289	0.00268	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—SRC—epilepsy syndrome	0.000269	0.00249	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PRKCB—epilepsy syndrome	0.000266	0.00247	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IL6ST—epilepsy syndrome	0.000265	0.00246	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—SRC—epilepsy syndrome	0.000258	0.00239	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—FOS—epilepsy syndrome	0.000243	0.00225	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CASP8—epilepsy syndrome	0.000237	0.0022	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—FGF2—epilepsy syndrome	0.000215	0.00199	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—BCL2—epilepsy syndrome	0.000204	0.00189	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—RELA—epilepsy syndrome	0.000199	0.00185	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—MTOR—epilepsy syndrome	0.000195	0.00181	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IL1B—epilepsy syndrome	0.00018	0.00167	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—JUN—epilepsy syndrome	0.000175	0.00162	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—AKT1—epilepsy syndrome	0.000167	0.00155	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—AKT1—epilepsy syndrome	0.00016	0.00149	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—SRC—epilepsy syndrome	0.000157	0.00145	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—AKT1—epilepsy syndrome	9.73e-05	0.000902	CbGpPWpGaD
